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suboptimal trough values, the vancomycin dosing regimen in our neonatal department was changed
during 2012.
Objective: We aimed to document the need for validation of neonatal vancomycin dosing by exploring
serum trough levels achieved using 2 published dosing regimens (previous regimen: based on
postmenstrual age and serum creatinine and new regimen: based on postmenstrual age and postnatal
age) and to identify covariates associated with suboptimal vancomycin trough levels (o10 mg/L).
Methods: Routine therapeutic drug monitoring serum trough levels quantified after initiation of intra-
venous vancomycin therapy and clinical covariates were retrospectively collected. Median vancomycin
trough levels of both dosing regimens were compared using the Mann-Whitney U test. The influence of
continuous and dichotomous covariates on achieving a suboptimal trough level was explored using the
Van Elteren test (stratified Mann-Whitney U test) and Mantel-Haenszel test (stratified χ2 test),
respectively. Covariates significant in monovariate analysis were subsequently included in a logistic
regression analysis.
Results: In total, 294 observations (median current weight 1870 g [range ¼ 420–4863 g] and median
postmenstrual age 35.07 weeks [range ¼ 25.14–56.00 weeks]) were included. Using the previous and
new dosing regimens, 66.3% and 76.2% of trough levels, respectively, were below 10 mg/L. Overall,
suboptimal vancomycin trough values were significantly associated with lower weight (birth weight and
current weight) and age (gestational age and postmenstrual age).
Conclusions: The majority of vancomycin trough levels in neonates achieved using 2 published dosing
regimens did not reach the target of 10 mg/L. This illustrates the urgent need for prospective validation of
neonatal vancomycin dosing regimens. We anticipate that dosing regimens integrating covariates
reflecting general physiological maturation and renal maturation, as well as disease characteristics,
could improve vancomycin exposure in neonates.
& 2014. The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
According to the Neonatal Research Network of the National
Institute of Child Health and Human Development, 21% of very–
low-birth weight infants experience at least 1 episode of late-onset
sepsis (LOS), a major cause of morbidity and mortality in thisInc. This is an open access article u
eonatal Intensive Care Unit,
ven, Belgium.
).specific population. Gram-positive bacteria are the most common
isolated pathogens (70%) causing LOS, with coagulase-negative
staphylococci accounting for 48% of the isolates.1 Vancomycin, a
glycopeptide antibiotic, is frequently used to treat these patho-
gens. However, an optimal vancomycin dosing regimen for neo-
nates is not available and prospective validation of published
dosing guidelines is lacking.
In adults, an AUC0–24 divided by the MIC for a given pathogen
Z400 is considered to be the best predictor of vancomycin
efficacy.2,3 During routine clinical care, vancomycin serum trough
concentrations are used as a surrogate marker for AUC, aiming tonder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Table I
Intermittent vancomycin dosing regimens* for neonates as retrieved in reference handbooks.4–12
Reference PMA (wk) PNA (d)
Current
weight (g)
Creatinine
(mg/dL)
Dose
(mg/kg) Interval (h)
Neofax® 20114 and
The Harriet Lane Handbook 20125 and
The Sanford guide 2012-20136
r29 0–14 10 (bacteremia),
15 (meninigitis)
18
414 12
30–36 0–14 12
414 8
37–44 0–7 12
47 8
Z45 any PNA 6
British National Formulary for children 20117 o29 15 24
29–35 12
435 8
Neonatal Formulary 20118 o29 GA 0–7 15 24
47 12
29–35 12
36–44 8
444 6
Dutch Children’s Formulary9 o7 10 12
7–28 8
Nelsons's texbook of Pediatrics 200710 r7 o1200 15 24
1200–2000 7.5–11.3 12–18
42000 15 12
Any weight 12 (Meningitis)
47 o1200 24
1200–2000 5–7.5 8–12
42000 15 8
7–28 Any weight 10 -15 8 (Meningitis)
Red Book 201211 o0.7 15 12
0.7–0.9 20 24
1–1.2 15 24
1.3–1.6 10 24
41.6 15 48
Neonatal and pediatric pharmacology 2011
(Drug formulary for the newborn)12
o7 o1200 15 24
1200–2000 10–15 12–18
42000 8–12
47 o2000 8–12
42000 15–20 8
GA = gestational age in the footnote, PMA ¼ postmenstrual age, PNA ¼ postnatal age.
n Data are adapted to mg/kg/dose.
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venous administration.3 In neonates, there is no firm correlation
between serum trough levels and vancomycin efficacy. Conse-
quently serum vancomycin target levels for this special population
are derived from adults. However, neonates differ from adults
based on their body composition, maturation aspects, specific
physiology, and diseases. Furthermore, neonates are considered
immunocompromised hosts due to the immaturity of their innate
immune system.
The fact that we have been using vancomycin in neonatal care
for more than half a century, but are still searching for the optimal
dosing regimen and efficacy targets confirms the complexity of
neonatal vancomycin pharmacology. These deficits can also be
noticed in daily clinical care. First of all, clinicians are confronted
with a diversity of dosing regimens presented in commonly used
handbooks (Table I).4–12 Second, subtherapeutic vancomycin
trough levels are still frequently observed in neonates.
Because many neonates displayed vancomycin trough levels
below the target value (needing subsequent dosing adaptation)
when using a previously published postmenstrual age (PMA) and
serum creatinine-based dosing regimen,13 we decided to introduce
the PMA and postnatal age (PNA)-based Neofax® dosing approach
in our neonatal department during 2012 as new vancomycin
dosing regimen.4 To illustrate the need for prospective validation
of neonatal vancomycin dosing regimens, we explored serum
trough levels achieved using both dosing approaches and, by
pooling all observations, we aimed to identify covariatesassociated with vancomycin serum trough levels below 10 mg/L
in neonates and young infants.Patients and Methods
Study population, data collection, and ethics
Vancomycin therapeutic drug monitoring (TDM) observations
of neonates and young infants treated with intravenous vancomy-
cin, mainly for (suspected) LOS (ie, 472 hours after birth), in the
neonatal intensive care unit of the University Hospitals Leuven,
Leuven, Belgium, between June 2011 and December 2012, were
considered for inclusion in our retrospective study. Our patient
population consists of (pre)term neonates, inborn or transferred,
in need of specialized care related to prematurity, infections,
perinatal asphyxia, congenital diseases (eg, surgery for cardiopa-
thy, congenital diaphragmatic hernia, or esophageal atresia), or
other diseases. Clinical characteristics at birth (eg, gestational age
[GA] in weeks, birth weight in grams), as well as characteristics at
the moment of TDM (PMA inweeks), PNA (in days), current weight
(in grams), concurrent treatment with ibuprofen (yes/no) or
dopamine (yes/no), respiratory support (continuous positive air-
way pressure or mechanical ventilation) (yes/no), mechanical
ventilation (conventional or high frequency) (yes/no), patent
ductus arteriosus (yes/no), positive blood culture (yes/no), serum
creatinine concentration (in milligrams per deciliter), serum
Table II
The 2 vancomycin dosing regimens evaluated in this study. (A) Previous dosing
regimen (2011) based on postmenstrual age (PMA) and serum creatinine, published
by Anderson et al.13 B) New dosing regimen (2012, Neofax®4) based on PMA and
postnatal age (PNA) and limited to sepsis indication.
(A)
PMA (wk) Creatinine (mg/dL) Dose (mg/kg) Interval (h)
o29 15 24
29–35
o0.6
15
12
40.6 24
435
o0.6
15
8
40.6 12
(B)
PMA (wk) PNA (d) Dose (mg/kg) Interval (h)
r29 0–14 10 18
414 12
30–36
0–14 10 12
414 8
37–44
0–7 10 12
47 8
445 All 10 6
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concentration (in milligrams per liter) were extracted from the
patient files. The daily nursing progress reports were used to
collect data regarding vancomycin prescription (dose and interval).
Results were excluded if data regarding vancomycin prescription
could not be obtained or in case of an administration or sampling
time error. We aimed to document early vancomycin exposure (ie,
after 24 hours of treatment initiation), therefore only first trough
levels were included. The ethics board of our hospital approved
the study protocol.Vancomycin indication, administration, and TDM assay
Vancomycin (Vancocin, Elly Lilly, Brussels, Belgium)® combined
with amikacin, is used as standard therapy for (suspected) late
onset sepsis in our department and administration occurs as an
intravenous infusion over 60 minutes. Add-on therapy of vanco-
mycin for other indications (eg, severe early onset sepsis or
prophylaxis) is limited. The previous vancomycin dosing regimen
(based on PMA and creatinine) (Table IIA) was used between June
2011 and June 2012.13 The new dosing regimen (based on PMA and
PNA) (Table IIB) was introduced during June 2012.4 Because we
noticed no improvement in trough levels during clinical practice,
we believed it to be inappropriate to continue with this new
regimen. Therefore, only data up to December 2012 were available
for inclusion. As part of routine clinical care, blood samples for TDM
were collected at the end of the dosing interval, in most cases 24
hours after treatment onset. Serum vancomycin assay was per-
formed either with a particle-enhanced turbidimetric inhibition
immunoassay method (Siemens Dimension; Dade Behring, Deer-
field, Illinois) (June 2011–October 2012) or with an enzyme multi-
plied immunoassay technique (Cobas c702; Roche Diagnostics,
Basel, Germany) (November 2012–December 2012). During Novem-
ber 2012, the assay was changed throughout the entire hospital for
unrelated (ie, no clinical) reasons. The hospital laboratory has a
quality system that conforms to ISO15189. This implies clinical
interchangeability of results is verified when changing from 1 assay
to another. To avoid censoring of values below the lower limit of
quantification (2 mg/L), these concentrations were replaced by a
lower limit of quantification/2 (ie, 1 mg/L) as suggested in the
literature.14 An enzymatic technique (Cobas c702 module) was usedto quantify serum creatinine levels.15 A colorimetric method
(bromcresol green) was used to quantify serum albumin
concentrations.
Statistical analysis
Comparison of continuous clinical characteristics as well as
median vancomycin serum trough level between observations of
both dosing regimens was determined using the Mann-Whitney U
test. Comparison of dichotomous covariates was done by χ2 test.
On the total dataset, the influence of continuous and dichoto-
mous covariates on achieving suboptimal trough levels (o10 mg/L)
was explored using the Van Elteren test (stratified Mann-Whitney
U test) and Mantel-Haenszel test (stratified χ2 test), respectively.
Stratification was done for dosing regimen. Covariates significantly
associated with suboptimal vancomycin trough levels in mono-
variate analysis were entered in a logistic regression analysis.
Spearman correlation was used to evaluate relations between
continuous variables before inclusion in the logistic regression
analysis. A P value o0.05 was considered statistically significant.
Vancomycin serum trough levels and clinical characteristics
were presented as median and range or incidence. Statistical
analyses were performed using MedCalc12 (MedCalc Software,
Mariakerke, Belgium) and the coin package in R version 3.0.2
(R Foundation for Statistical Computing, Vienna, Austria).Results
Dataset
In total, 593 TDM observations were obtained in 223 patients.
Sixty-one observations were excluded based on criteria summar-
ized in Figure 1. Another 238 observations, collected after dosing
adjustments, were also excluded. The final dataset comprised 294
vancomycin TDM observations: 193 observations of the previous
(2011) dosing regimen, 101 of the new (2012) dosing regimen.
Both cohorts had comparable clinical characteristics, but differ-
ences for serum albumin and creatinine were documented
(Table IIIA). Taking into account the 294 vancomycin treatment
episodes, indications to start vancomycin were (suspected) sepsis
(87.7%, of which 8.8% were early onset cases [r72 hours after
birth] and 78.9% were late onset cases), presence of foreign body
material (eg, thoracic drain or pacemaker [2.4%], prophylaxis such
as perforation umbilical catheter or disconnection ventricular-
external drain [2.7%], [sub]cutaneous wound infection [3.4%],
pneumonia [3.1%], or unknown [0.7%]. Incidences of indications
stratified by dosing regimen and by age at initiation of therapy are
presented in Table IIIB.
Sixteen vancomycin trough values were below the lower limit
of quantification. Median vancomycin concentration of samples
achieved using the same dosing regimen (Neofax®), but with
different vancomycin quantification assays used during the study
period, were compared and did not differ significantly (5.9 mg/L
Behring vs 5.5 mg/L Roche; Mann-Whitney U test, P ¼ 0.773).
Previous versus new dosing regimen
The previous dosing regimen (Table II) resulted in a signifi-
cantly higher vancomycin trough concentration compared with
the new regimen (median 7.8 mg/L [range ¼ 1–37.8 mg/L] vs
median 5.8 mg/L (range ¼ 1–20.1 mg/L) (Figure 2). In the previous
regimen, 128 out of 193 (66.32%) of observations were o10 mg/L
and 65 out of 193 (33.68%) were Z10 mg/L. In the new regimen,
77 out of 101 (76.24%) of observations were o10 mg/L and 24 out
of 101 (23.76%) reached levels Z10 mg/L.
Table IIIB
Indications to start vancomycin therapy. Differences in incidences between both
dosing regimens were explored using χ2 test.
Vancomycin
indication
Previous dosing
regimen (n ¼ 193)
New dosing
regimen (n ¼ 101)
P*
Incidence (%)
Early (r72 h after
birth)
26/193 (13.47) 15/101 (14.85) 0.8830
Foreign body
material
4 (2.07) 3 (2.97) 0.9388
Prophylaxis 2 (1.04) 2 (1.98) 0.8939
(Suspected) EOS 16 (8.29) 10 (9.90) 0.8059
(Sub)cutaneous
wound infection
4 (2.07) 0 0.3541
Late (472 h after
birth)
167/193 (86.53) 86/101 (85.15) 0.8830
Prophylaxis 3 (1.55) 1 (0.99) 0.8939
(Suspected) LOS 150 (77.72) 82 (81.19) 0.5880
(Sub)cutaneous
wound infection
4 (2.07) 2 (1.98) 0.7031
Pneumonia 8 (4.15) 1 (0.99) 0.2564
Unknown 2 (1.04) 0 0.7799
EOS ¼ early onset sepsis; LOS ¼ late onset sepsis; n ¼ number of observations.
n P o 0.05 was considered statistically significant.
All vancomcyin
TDM results
N = 593
61 results excluded:
- missing data regarding prescription (22)
- administration error (12)
- sampling time error (18)
- follow up after toxic concentration (9)
TDM results
initially retained
N = 532
238 results excluded:
- TDM after dosing adjustment
First TDM results
N = 294  
Previous dosing regimen (2011)13
N = 193
New dosing regimen (2012)4
N = 101
Figure 1. Flowchart of included vancomycin therapeutic drug monitoring (TDM)
observations.
Table IIIA
Clinical characteristics of included vancomycin trough concentrations achieved by the
covariates between both cohorts, Mann–Whitney U test and χ2 test were used, respecti
Covariate Previous dosing regimen (n ¼ 193
Continuous
Gestational age (wk) 32.86 (24.57–41.43)
Postnatal age (d) 13 (1–169)
Postmenstrual age (wk) 34.71 (25.14–49.86)
Birth weight (g) 1540 (420–4680)
Current weight (g) 1818 (500–4715)
Albumin (g/dL) 31.95 (17.40–50.40)‡
Creatinine (mg/dL) 0.43 (0.14–1.18)||
Dichotomous
Patent ductus arteriosus 12/153
Concurrent ibuprofen 10/193
Concurrent dopamine 22/193
Positive blood culture 64/192
Respiratory support 130/193
Invasive respiratory support 80/193
n ¼ number of observations.
n Data are presented as median and range (continuous covariates) or incidence (dic
† P o 0.05 was considered statistically significant.
‡ n ¼ 164.
§ n ¼ 89.
|| n ¼ 178.
¶ n ¼ 93.
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Overall, 205 out of 294 (69.73%) vancomycin trough levels were
o10 mg/L, whereas 89 out of 294 (30.27%) reached levels Z10
mg/L. Clinical characteristics of both groups (ie, trough level o10
vs Z10 mg/L) are presented in Table IV. Lower age (GA and PMA),
lower weight (birth weight and current weight), and higher PNA
were significantly associated with suboptimal trough levels and
these covariates were considered for inclusion in a logistic regres-
sion analysis. High correlation coefficients were documented
between PMA and GA (r ¼ 0.83), and between birth weight and
current weight (r ¼ 0.89). Because PMA combines GA (representingprevious versus the new dosing regimen. To explore continuous and dichotomous
vely.*
) New dosing regimen (n ¼ 101) P†
32.14 (24.86–41) 0.9862
12 (2–121) 0.4445
35.29 (25.43–56) 0.5950
1850 (440–4150) 0.3821
2060 (420–4863) 0.9237
31 (12.90–39.70)§ 0.0290
0.49 (0.13–1.19)¶ 0.0429
5/80 0.8581
6/101 0.9985
11/101 0.9494
30/101 0.6163
71/101 0.7020
42/101 0.9183
hotomous covariates).
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Figure 2. Vancomycin serum trough concentrations (in milligrams per liter)
achieved by the 2 vancomycin dosing regimens used in our neonatal department,
presented as boxplots (Mann-Whitney U test, P o 0.05). PMA ¼ postmenstrual
age; PNA ¼ postnatal age.
A. Vandendriessche et al. / Current Therapeutic Research 76 (2014) 51–57 55prenatal maturation) and PNA (representing postnatal matura-
tion), GA was retained for inclusion instead of PMA. Because
vancomycin is usually not administered in the first days of life,
current weight was chosen instead of BW. The final covariates
entered in the logistic regression analysis were GA, PNA, current
weight, and dosing regimen. Results of the analysis are presented
in Table V.Discussion
Up to 70% of vancomycin serum trough levels in neonates and
young infants, achieved using 2 published dosing regimens for
intermittent intravenous vancomycin administration, were below
the target level of 10 mg/L. This finding illustrates the urgent need
for optimization with subsequent prospective validation of sug-
gested vancomycin dosing regimens in this specific population.
We documented that weight (birth weight and current weight)
and age (GA, PMA, and PNA)—both reflecting ontogeny—wereTable IV
Clinical characteristics of all included vancomycin trough concentrations as well as for the
continuous and dichotomous covariates on achieving vancomycin trough concentrations
Haenszel test (stratified χ2 test) was used, respectively. Stratification was done for dosin
Covariates All TDM data (n ¼ 294) TDM o10 m
Continuous
Gestational age (wk) 32.29 (24.57–41.43) 31 (24.57–41)
Postnatal age (d) 13 (1–169) 15 (1–169)
Postmenstrual age (wk) 35.07 (25.14–56) 33.28 (25.14–
Birth weight (g) 1575 (420–4680) 1435 (420–41
Current weight (g) 1870 (420–4863) 1567 (487–47
Albumin (g/dL) 31.60 (12.90–50.40) 32 (12.9–50.4
Creatinine (mg/dL) 0.43 (0.13–1.19) 0.43 (0.23–1.1
Dichotomous
Patent ductus arteriosus 17/233 (7.3%) 13/172
Concurrent ibuprofen 16/294 (5.4%) 11/205
Concurrent dopamine 33/294 (11.2%) 23/205
Positive blood culture 94/293 (32.1%) 72/205
Dosing regimen (previous/new) 193 (65.6%) / 101(34.4%) 128/77
Respiratory support 201/294 (68.4%) 136/205
Invasive respiratory support 122/294 (41.5%) 77/205
χ2 ¼ test statistic Mantel-Haenszel test; k ¼ test statistic Van Elteren test; n ¼ numbe
n Data are presented as median and range (continuous covariates) or incidence (dic
† Statistically significant at P o 0.05.
‡ To explore the impact of dosing regimen on achieving trough concentrations o omajor covariates associated with vancomycin serum trough levels
in neonates (Table IV). This can be explained by the fact that
developmental changes in physiology are most prominent in early
life and influence drug disposition (ie, pharmacokinetics).16,17
Especially small (low birth weight, current weight) and immature
(low GA, PMA) babies showed vancomycin trough concentrations
below 10 mg/L. Their higher body water content, resulting in a
larger distribution volume for hydrophilic drugs (eg, vancomycin)
compared with older neonates, infants, and adults, can in part
contribute to the low TDM values observed. Besides changes in
body composition with increasing age, also renal function (and
consequently renal drug clearance) displays maturation. This
maturation is related to conditions at birth (eg, birth weight and
GA) and conditions after delivery (eg, PNA, ibuprofen administra-
tion, and perinatal asphyxia).18,19 The role of renal tubular func-
tions on neonatal drug clearance—and more specifically on
vancomycin clearance—is at present not yet unveiled.
The same holds true for the influence of specific diseases on
vancomycin disposition in neonates. To illustrate this, the vanco-
mycin trough value of 37.8 mg/L (outlier on Figure 2) was
documented in a girl with GA 39 weeks and PNA 4 days, during
the rewarming phase after hypothermia therapy for severe peri-
natal asphyxia. Because C-reactive protein levels increased while
receiving amikacin and amoxicillin, vancomycin was added on day
3. Serum creatinine was normal and amikacin trough level was
only slightly elevated (4.1 mg/L). Vancomycin prescription, admin-
istration, and TDM sampling times were in line with our local
procedures, but an error in drug handling before administration
cannot be excluded. Although asphyxia itself can impair renal
function and hypothermia can reduce renal blood flow (and
consequently renal drug clearance)20,21 the influence of these
events on neonatal vancomycin disposition is at present unknown.
We anticipate that optimized neonatal vancomycin dosing
regimens should take into account covariates representing matu-
ration but also disease characteristics22 and coadministration of
drugs influencing renal function, but these covariates are not yet
well considered in the currently proposed dosing regimens.
Besides the above-mentioned patient-specific characteristics,
the absence of optimal vancomycin efficacy targets, drug-specific
characteristics, and quantification assays used can also contribute
to variability in neonatal vancomycin exposure and can complicatesubgroups with trough concentrations o or Z10 mg/L. To explore the influence of
o or Z10 mg/L, the Van Elteren test (stratified Mann-Whitney U test) and Mantel-
g regimen.*
g/L (n ¼ 205) TDM Z10 mg/L (n ¼ 89) Test P
k
35.71 (24.86–41.43) 23.95 o0.0001†
10 (1–102) 8.25 0.0041†
56) 38.28 (25.43–53.28) 14.11 0.0002†
50) 2380 (440–4680) 26.51 o0.0001†
15) 2535 (420–4863) 21.03 o0.0001†
) 31.15 (18.4–42.9) 1.38 0.2399
8) 0.43 (0.13–1.19) 2.55 0.1103
χ2
4/61 0.0001 0.9939
5/89 0.027 0.8688
10/89 0.037 0.8478
22/88 2.655 0.1032
65/24 2.628 0.1044‡
65/89 1.1052 0.2931
45/89 3.8257 0.0505
r of observations; TDM ¼ therapeutic drug monitoring.
hotomous covariates). In all tests, degrees of freedom were equal to 1.
r Z10 mg/L, standard χ2 was used.
Table V
Logistic regression analysis with vancomycin serum trough levels o10 mg/L (¼ 1) or Z10 mg/L (¼ 0) as the dependent variable. Two hundred ninety-four vancomycin
serum trough levels were included.*
Covariate Coefficient β SE P OR 95% CI
Constant 2.8523 1.6130 0.0770 17.327
Gestational age −0.0486 0.0616 0.4296 0.9525 0.8443–1.0747
Postnatal age 0.0220 0.0088 0.0113† 1.0222 1.0050–1.0397
Current weight −0.0005 0.0003 0.1049 0.9995 0.9990–1.0001
Dosing regimen 0.6363 0.3008 0.0344† 1.8895 1.0478–3.4075
OR ¼ odds ratio.
n Degrees of freedom were equal to 1 for all covariates.
† P o 0.05 was considered statistically significant.
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no clear relationship between clinical response and indices of
systemic vancomycin exposure in neonates. Based on studies in
adults, an AUC0–24/MIC ratio Z400 has been recommended to
achieve effectiveness. In clinical practice, vancomycin trough
concentrations are used as surrogate marker and should be kept
above 10 mg/L to correspond with an AUC0–24/MIC ratio Z400, if
the MIC is o1 mg/L.3,24,25 This assumption is derived from adults
receiving 12-hourly vancomycin dosing. Moreover, trough concen-
trations depend on dose frequency.26 In neonates, it is unknown
what the optimal trough targets should be. Although some authors
recommend directly monitoring AUC, the optimal parameter for
vancomycin efficacy in neonates and young children remains
unresolved.26–29
It should be emphasized that the staphylococcal targets (coag-
ulase-negative staphylococci) for vancomycin use in neonates and
their corresponding local MIC values are not comparable with the
adult setting in which vancomycin is predominantly used to cure
methicillin-resistant Staphylococcus aureus infection.30 Second,
vancomycin is bound to albumin and immunoglobulin A in plasma
and only the unbound drug is pharmacologically active. However,
data in neonates concerning the extent of protein binding as well
as the disposition of vancomycin in deep body compartments are
limited. We would like to stress that these pharmacokinetic
aspects need further research to improve insight into the behavior
of vancomycin in neonates. Finally, currently used analytical
methods for vancomycin quantification contribute to variability
in TDM results and limit the transferability of vancomycin phar-
macokinetic models—and subsequently model-derived dosing
regimens—to other centers.31,32 Therefore, the introduction of a
more precise method, such as liquid chromatography-tandem
mass spectroscopy (LC-MS/MS), which is considered to be the
gold standard reference method, should be considered.33,34 The
high specificity, sensitivity, and accuracy of LC-MS/MS makes it
more suitable for pharmacokinetic studies compared with immu-
noassays, which in general suffer from nonspecific interference
from related compounds or matrix effects33,35,36 or, in the case of
vancomycin, its crystalline degradation products. High instrument
costs, greater technical complexity, speed, and turnaround of
sample analysis, are considered as the main disadvantages of LC-
MS/MS. However, careful choice of sample preparation method
and internal standard, and validation of assays, should be able to
avoid the majority of pitfalls.33 Bijleveld et al36 recently reported
that LC-MS/MS documented slightly lower vancomycin concen-
trations than Fluorescence Polarization Immunoassay. However,
the applicability of their LC-MS/MS was only tested in 3 neonatal
patients.36 Therefore, paired analysis of neonatal vancomycin
plasma concentrations using immunoassay versus LC-MS/MS in a
large neonatal cohort is currently not yet available, but could be of
relevance to optimize neonatal vancomycin dosing.
During the past decade, several neonatal vancomycin dosing
regimens have been proposed. The previous dosing regimen usedin our unit seemed to be slightly better than the Neofax® regimen,
but both were unable to reach sufficient median vancomycin
trough levels. As soon as preliminary results of our study were
available, we decided to reintroduce the previous approach (based
on PMA and serum creatinine) until prospectively validated
improved dosing appears. Our observations are, to a certain extent,
in line with Badran et al,37 who documented that only 51% of
neonates attained a predefined vancomycin trough level between
5 and 10 mg/L using the Neofax® vancomycin dosing regimen and
33% of their trough concentrations were below 5 mg/L.
We are aware that our analysis is only based on trough levels
quantified after initiation of therapy because we aimed to achieve
drug levels in the target range within a short time. We consider
our covariate analysis as exploratory. More precise and predictive
analyses require a population pharmacokinetic modelling
approach in which available pharmacokinetic data can be used
for the exploration of the most optimal vancomycin pharmacody-
namic target in neonates, as well as for Monte Carlo simulations
exploring different vancomycin administration modes (eg, loading
dose in intermittent dosing) to achieve early targeted vancomycin
exposure. However, this is beyond the intention of our study.
Nevertheless, the large study size and the comparison of 2 recently
published vancomycin dosing regimens to document the emer-
gence of prospective validation of neonatal vancomycin dosing are
relevant strengths.
We conclude that 66.3% and 76.2% of vancomycin trough levels
in neonates achieved using 2 published dosing regimens did not
reach the target of 10 mg/L. This is relevant, but just 1 of the
problems related to vancomycin treatment of neonates. Prospec-
tive validation of vancomycin dosing regimens, but also further
exploration of pharmacokinetic (eg, protein binding, influence of
renal [tubular] functions on clearance) and pharmacodynamic (eg,
optimal exposure targets) aspects of vancomycin in neonates is
urgently needed.Acknowledgments
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